{"title": "PDF", "author": "PDF", "url": "https://www.scienceopen.com/document_file/398b7b2e-b3f7-4199-ae3e-a121a249ac1e/PubMedCentral/398b7b2e-b3f7-4199-ae3e-a121a249ac1e.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Effectiveness of SARS-CoV-2 mRNA Vacc ines for Preventing Covid -19 Hospitalizations in the United States Authors: 1. Mark W. Tenfo rde, MD, PhD CDC COVID-19 Response Team, Atlan ta, Georgi a 2. Manish M. Pat el, MD CDC COVID-19 Response Team, Atlan ta, Georgi a 3. Adit A . Gind e, MD, MPH Departmen t of Emergency Medicine , Uni versity of Colorado School of Medicin e, A urora, Colorado 4. David J. Douin, MD Departmen t of Anes thesiol ogy, Universit y of Colorado School of Medicine, A uror a , Colorado 5. H. Keipp Talbo t, MD, MPH Departmen ts of Medicine and Heal th Policy, Vanderbilt Universi ty Medical Cen ter , Nashville, Tennessee 6. Jona than D. Casey, MD, MSci Departmen t of Medicin e, Vander bilt Uni versity Medical Cent er, Nashville, Tenn es see 7. Nicholas M. Mohr, MD, MS Departmen t of Emergency Medicine , Uni versity of Iowa, Iowa City, Iowa 8. Anne Zepeski, PharmD Departmen t of Emergency Medicine , Uni versity of Iowa, Iowa City, Iowa 9. Manjusha Gagla ni, MBBS Baylor Scot t and Whi te He alth, Te xas A& M University College of Medicin e, Templ e, Texas 10. Tresa McN eal, MD Baylor Scot t and Whi te He alth, Te xas A& M University College of Medicin e, Templ e, Texas 11. Shekhar Gh amande , MD Baylor Scot t and Whi te He alth, Te xas A& M University College of Medicin e, Templ e, Texas 12. Nath an I. Sh apiro , MD, MPH Departmen t of Emergency Medicine , Be t h Israel Deacon ess Medical Cen ter , Bost on, Massachuset ts 13. Kevin W. Gibbs, MD Departmen t of Medicin e, Wake F ores t School of Medicine, Winston-Sal em, No rth Carolina 14. D. Clark Files, MD Departmen t of Medicin e, Wake F ores t School of Medicine, Winston-Sal em, No rth Carolina 15. David N. Hager, MD, PhD Departmen t of Medicin e, Joh ns Hopkins University School of Medicin e, Bal timore , Maryland 16. Arber Sh ehu, MD Departmen t of Medicin e, Joh ns Hopkins University School of Medicin e, Bal timore , Maryland 17. Mat thew E. Prekker, MD, MPH Departmen t of Emergency Medicine and Medicine, H ennepin Coun ty Medical Cen ter, Minneapol is, Minneso ta 18. Heidi L. Erickson, MD Departmen t of Medicin e, Henn epin Cou ota . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 19. Mat thew C. Exline , MD, MPH Departmen t of Medicin e, The Ohio S ta te University, Columbus, Ohio 20. Michelle N . Go ng, MD Departmen t of Medicin e, Mon tefior e He alth System, Al ber t Einstein Colleg e of Medicine, Br onx , New York 21. Amira Moh amed, MD Departmen t of Medicin e, Mon tefior e Me dical Center , Bron x, N ew York 22. Daniel J. H enning, MD, MPH Departmen t of Emergency Medicine , Uni versity of Washington, S eat tle , Washingt on 23. Jay S. St eingrub, MD Departmen t of Medicin e, Baysta te M edi cal Center, Sp ringfield, Massachus et ts 24. Itha n D. t of Medicin e, In termoun tain Medical Cent er, Mu rray, U tah and Unive rsity of Utah, Salt Lake City, Utah 25. Samuel M. B rown, MD, MS Departmen t of Medicin e, In termoun tain Medical Cent er, Mu rray, U tah and Unive rsity of Utah, Salt Lake City, Utah 26. Emily T. Martin, PhD School of Public Health, Universi ty of Michigan, Ann Arb or, Michigan 27. Arnold S . Mont o, MD School of Public Health, Universi ty of Michigan, Ann Arb or, Michigan 28. Akram Khan, MD Departmen t of Medicin e, Or egon Heal th and Sciences Universi ty, Portland , Or ego n 29. C. Terri Hough, MD Departmen t of Medicin e, Or egon Heal th and Sciences Universi ty, Portland , Or ego n 30. Laurence Buss e, MD Departmen t of Medicin e, Emory Universi ty, Atlan ta, Geo rgia 31. Caitlin C. ten Lohuis, ACNP-BC Emory Critical Care Cente r, Emory Heal th care, A tlan ta, Georgia 32. Abhijit Duggal, MD Departmen t of Medicin e, Cleveland Clini c, Cleveland, Ohio 33. Jennife r G. Wilson, MD Departmen t of Emergency Medicine , Sta nford University School of Medicin e, St a nford, California 34. Alex andra June Gord on, MD Departmen t of Emergency Medicine , Sta nford University School of Medicin e, St a nford, California 35. Nida Qadi r, MD Departmen t of Medicin e, Universi ty of C alifornia-Los Angeles, Los Angel es, Califo rnia 36. Steven Y. Chang, MD, PhD Departmen t of Medicin e, Universi ty of C alifornia-Los Angeles, Los Angel Califo rnia 37. Christophe MD, MHS Departmen Medicin e, Universi ty of Miami, Miami, Florid a 38. Hayley B. Ge rshengo rn, MD Departmen t of Medicin e, Universi ty of Miami, Miami, Florid a 39. Hilary M. Babcock, MD, MPH Departmen t of Medicin e, Washing ton U niversity, St. Louis, Missouri . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint 40. Jenni e H. Kwon, DO, MS Departmen t of Medicin e, Washing ton U niversity, St. Louis, Missouri 41. Nat asha Halasa , MD, MPH Departmen t of Pediat rics, Vanderbil t Uni versity Medical Cent er, Nashville, Tenn es see 42. James D. Chappell , MD, PhD Departmen t of Pediat rics, Vanderbil t Uni versity Medical Cent er, Nashville, Tenn es see 43. Adam S. Lauring, MD, PhD Departmen ts of Int ernal M edicine an d M icrobiology and Immunology, Universi ty of Michigan, Ann Arbo r, Michigan 44. Carlos G. Grijalva, MD, MPH Departmen t of Heal th Policy, Vanderbilt University Medical Cen ter , Nashville , Ten nessee 45. Todd W. Rice, MD, Departmen t of Medicin e, Vander bilt Uni versity Medical Cent er, Nashville, Tenn es see 46. Ian D. Jon es, MD Departmen t of Emergency Medicine , Vanderbil t University Me dical Cente r, N ash ville, Tennesse e 47. William B. S tubblefield , MD, MPH Departmen t of Emergency Medicine , Vanderbil t University Me dical Cente r, N ash ville, Tennesse e 48. Adrien ne Baughman Departmen t of Emergency Medicine , Vanderbil t University Me dical Cente r, N ash ville, Tennesse e 49. Kelsey N. Womack, PhD Vanderbilt Insti tut e for Clinical and Trans lational R esea rch, Vander bilt Unive rsity Medical Vand erbil U niversity Medical Cen ter, Nashville, Ten n essee 51. Kimberly W. Har t, MA Departmen t of Biost atistics, Vand erbil t U niversity Medical Cen ter, Nashville, Ten n essee 52. Yuwei Zhu, MD, MS Departmen t of Biost atistics, Vand erbil t U niversity Medical Cen ter, Nashville, Ten n essee 53. Samanth a M. Olso n, MPH CDC COVID-19 Response Team, Atlan ta, Georgi a 54. Meagan S teph enson, MPH CDC COVID-19 Response Team, 55. Steph anie J . C COVID-19 Response Team, Atlan ta, Georgi a 56. Miwako Kobayashi, MD CDC COVID-19 Response Team, Atlan ta, Georgi a 57. Jennife r R. Ver ani, MD* CDC COVID-19 Response Team, Atlan ta, Georgi a 58. Wesley H. S elf, MD, MPH* Departmen t of Emergency Medicine and Vanderbilt Insti tut e for Clinical and Trans lational Research , Vanderbil t Universi ty Medical Center, Nashville, Ten nesse e For the Influenza a nd Oth er Viruses in th e Acutely Ill (IVY) Network ** * Dr. Self and Dr. Veran i contribu ted equ ally to this work. list of investiga tors and colla bora tors in th e Influenz a and oth er Viruses in the Acu tely Ill (IVY) Netwo rk is available in tar y Appendix A . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv Cent er; 312 xford Hous e, 1313 ashville, Tenfor de, MD, PhD; Cente rs for Disease Control and Preven tion ; 1600 Clifton Road : 404-861-0404. Funding: Primary funding for this study was provided by the Cent ers for Disease Cont rol an d Prevention (75D30121F00002 ). The REDCap data tool was supported by a and Transl ational Sci ence Award (UL1 TR002243 ) from the Cente r for Advancing Translatio nal Sciences . Disclaimer: The findings and conclusions in this repo rt ar e those of t he au thors and d o not ne cessarily repr esent the official position of the Cent ers for Diseas e Control and Preve ntion is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv ABSTRACT Background: As SARS-CoV- 2 vaccination coverage incre ases in the U nite d Sta tes (US), ther e is a need t o underst and th e real-world effectiveness against sever e Covid-19 and among people at incre ased risk for poor outc case-con trol a nalysis of US adults hospitaliz ed Ma rch 11 - May 5, 2021, we evaluat ed vaccine effectiveness t o preve nt Covid-19 hospitalizati ons by comparin g odds of prior vaccination with an mRN A vaccine (Pfizer-BioNTech or M oder na) betwe en cases hospitaliz ed with Covid-19 and hospital-bas ed contr ols who test ed negative for S ARS-CoV-2. Results: Among 1210 particip ants, me dia n age was 58 years, 22.8% were Black, 13 .8% were Hispanic, and 20.6% had immunosuppressio n. SAR S-CoV-2 lineage B.1.1.7 was most common variant (59.7% of sequenced viruses). Full vaccina tion (rec eipt of two vaccine doses 14 days befor e illness onset) had been r eceived by 45/590 (7.6%) cases and 215/620 to 91.2%). Vaccine e ffectiveness was similar for Pfizer-BioNTech and Mode rna vaccines, and highest in adul 18-49 years (97.3%; ough Covid hospitaliza ti ons, 44 (97.8%) were 50 years old and 20 (44.4%) had immunosuppression . Vaccine effectivene highly eff ective for ting Covid-19 hospitalizations among US ad ul ts. SARS-CoV-2 vaccination was beneficia l for patien ts with immunosuppression, bu t effectiven . . CC-BY-NC-ND 4.0 International It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted 2021. ; ,000 deaths r elat ed to co ronavirus dise as e 2019 (Covid-19 ) occurred in th e Unit ed St ates (US) throu gh May 2021.[1] In December 2020, the Food and Drug Administra tion gran ted Eme rgency Use Autho rizati on for two messenger R NA (mRNA) vaccines (from Pfizer-BioNTech and Mode rna) aga inst severe acu te r espira tory syndrome c oronavirus 2 (SARS-CoV-2),[2 ] the virus that causes Covid-19. Widespr ead public h ealth ini tia tives res ulted in over 60% of the US adul t popula tion r eceiving at le ast one dose of a SA RS-CoV-2 vaccine by th e end of May 2021.[1] The mRNA vaccines have be en the p redo minate SAR S-CoV-2 vaccine products used in the US, with approxim ately 95% of vaccinated peo ple having received eit her a Pfizer-Bio NTech or Mode rna vaccine.[1] Phase 3 clinical trials of mRNA vaccines found a 94-95% reducti on in Covid-19 illness and near 100% protectio n against seve re Covid-19.[3, 4] However, thes e clinical tri als had few cases of hospitaliz ed Covid-19, and limited power to assess efficacy among persons with underlying illnesses who are a t high risk for severe Covid-19. As vaccine coverage incre ases, obse rvation al vaccine effectiveness evaluations a re impor tan t to und erst and how well the vaccines prot ect agains t Covid-19 in real-world settings across divers e popula tions, inclu ding immunocompromised hosts. Th e Centers for Disease Control and Preven tion (CDC) collaborat es with the Influ enza and Oth er Viruses i n the Acut ely Ill (IVY) Netwo rk to monito r th e effectiveness of SARS-CoV-2 vaccines for the preventi on of Covid-19 hospitaliz ations among US ad ults. In this analysis, we evaluat ed th e effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospital izations by vaccine produc t, by age grou p, and by underlying medical conditions , including immunosuppression.[5] METHO DS . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint Design The protocol and sta tistical an alysis plan for this project a re availabl e in th e suppl ementa ry rvation al case-control evaluati on of vaccine effectiveness by comparing the odds of an teced ent S versus control-pa tien ts without Covid-19. We included two control gr oups: 1) \"te st-negative\" contr ols presen ted with signs or symptoms of an acute r espira tory illness but tes ted nega t ive for SARS-CoV-2; and 2) \"syndrome-negative\" controls we re selec ted from hospit alized adults with out signs or symptoms of an acute respi ra tory illness and t est ed negative for SARS-CoV-2. Test-nega tive controls ar e commonly used in hospital-bas ed vaccine effectiven ess evaluations ;[6-9] in this test-nega tive design, utilizing a comparison group with t he same clinical syndrome and similar level of acuity as c ases reduces bi as due to differen tial hea lthcar e seeking beh p oten tial tive cont rols due to false-nega ti ve test esults using the test-n egative d e sign, particula rly for those pr esen ting late in the cours e of illness,[10] we included the second con trol group of hospitaliz Consistent with m ethod ologies for vaccine effectiveness evaluations r ecommend ed by Wo rld Health Organiza tion ,[11] SARS-CoV-2 vac cine coverage in bo th control groups se rved as a pro xy for background vaccination r ates in the sourc e p opulatio n for COVID-19 cases. Setting This surveillance activity was conducted by the IVY Netwo rk, a CDC-funded and pa tien ts hospitali zed from March 11 thro ugh May 5, 2021, at 18 academic medical cen ters i n 16 states. Each p articip ating insti tuti on , including CDC, reviewed and conduc ted t his activity con sistent with a pplicable fed eral law and C DC policy (45 C.F.R. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint part 46.102(l)(2), \u00a7552a ; 44 U.S.C. \u00a73 501 et seq.). The program was conducted as a pu blic heal t h surveillance activity withou t writ ten ormed consen t. Participants Sites scre ened hospi taliz ed adults 18 years old for pot ential eligibility th rough da ily review of hospital admission logs and elect ronic medical r e cords. Detail ed eligibili ty criteri a are sho wn in Supplementa ry Appendi x B. In b rief, Covid-19 cases included pati ents with a clinical syndrom e consistent with acute Covid-19 and a positive test for SA RS-CoV-2 within 10 days following symptom o nset.[13-15] Test-negative cont rols had a clinical syndrom e consisten t with acut e Covid-19 but test ed negative for S ARS-CoV-2. Syndrome-negative contr ols did not have a clinical syndrome consis ten t with Covid-19 and test ed nega tive for SARS-CoV-2. Individu al matching betwe en cases and con trols was not performe d. Sites ta rget ed a con trol rati o of app roxima tely 1:1 for each con trol group an d did not seek information on vaccina tion sta tus until af ter pa tien ts were includ ed. Data Collection Participants (or t heir p roxi es when par ticipants could no t answer medical qu estio ns) were interviewed by trained p ersonn el to collec t dat a on d emographics, medical condi tions, S ARS-CoV-2 vaccination, and other p ati ent char acte ristics. Add ition al information on und erlying medical condi tions and SARS-CoV-2 clinical testing was obt ained through st a ndardize d medical reco rd review. Laboratory Analysis Upper r espira tory specimens (nasal swab s or saliva) were collected , frozen, and sh ipped to a cen tr al labora tory at Vand erbil t University M edi cal Center (Nashville , Tennesse e). Speci mens underwen gene . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint cycle threshold <32 for a t leas t one of th e two RT-PCR targets were shipp ed to th e University of Michigan (Ann Arbor , Michigan) for viral whole genome sequ encing using the ART IC Network version 3 protocol o n an Oxfo rd Nan opor e Technol B).[17] cover age using Pangolin genomes.[18] Classi fication of Case-Control Status Final classification of ol sta tus was determin ed with conside rati on of both clinical SARS-CoV-2 testing comple ted a t local hospi tal labo r atori es and RT-PCR testing complet ed at the cen tral lab ora tory. Cases teste d positive for SA RS-CoV-2 by a clinical test o r cent ral labo rato ry RT-PC R test . Cases with SARS-CoV-2 detecte by RT-PCR with a cycle threshold >32 were includ ed in the a nalysis, but viral sequencing informati on was not availabl these cas Test-nega tive cont rols teste d negative for SARS-CoV-2 clinical and central tes ting. Patien ts initia lly classified as a test- negative cont rol who subsequen tly test ed positive for S ARS-CoV-2 by central RT-PCR testing were reclas sified as con trols test ed nega tive for SARS-CoV-2 by all clinical and central t esting. Pa tien ts included as syndrome-nega tive contr ols who subsequently t est ed positive for SA RS-CoV-2 in the central labora tory were exclud ed from the an alysis. Classi fication of Vaccination Status Details of SARS-CoV-2 vaccination, including dates and loca tion of vaccination , vaccine product , and lot number, wer e ascer taine d thro ugh a systematic process including pa tien t or pr ox y interview and source verification. So urces of documen tati on included vaccination car d, hospit al reco rd s, state vaccine registri es which were search ed at the ti me of interview and again ap prox imately 28 days later, and vaccine records re quest ed from clinics and pharmacies. Vaccine d oses were class ified as administer ed if source documen tati on was identified o r i f the pati ent/pro xy repo rte d a vaccine dose with a plausible date an d location of vaccination. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint The SARS-CoV-2 mRNA a two-dose se ries; p articip an ts were considered fully vaccinated 14 days afte r receipt of th e second vaccine dos e.[19] Vaccination sta tus was classified based on th e number of mRN A vaccine doses received b efore a r efer ence date , which was the date of symptom onse t for cases and t es t-negative con trols and d ate of hospi were classified as: unvaccinat ed if they had received no vaccine doses prior t o the refer ence da te ; parti ally vaccinated if they rec eived one dose 14 days before the ref erenc e dat e; and fully vaccinated i f they received bo th doses 14 days befo re the refer ence da te . As prot ective immunity from SARS-CoV-2 vaccines is not aft er the firs t dose,[12] ts who received a first dose <14 da ys before the r efere nce dat e were exclud ed from the an alysis. Patients who r eceived a SARS-CoV-2 vaccine tha t had no t been a utho rized in the US were e xcluded . Due to rece nt int roducti on of the Janssen (Jo hnson & Johnson) SARS-CoV-2 vaccine fo llowing its EUA in Februa ry 2021,[2] patients who rec eived this vaccine were also e xcluded . Statistical Analysis Vaccine effectiveness and 95% confidence inte rvals (95% CI) were dete rmined by comparing the odds of prior SARS-CoV-2 vaccination in case-pa ti ents and con trol-pa tien ts, calculat ed as: vaccine effectiveness = (1 - odds ratio) \u00d7 100%.[20] Primary vaccine effectiveness estimat es were calculat ed in adul ts of all ages for full vaccination versus unvaccinated and for p arti al vaccination versus unvaccina ted . Unadjust ed vaccine effectiveness was calculated with simple logistic r egres sion and then a mod el building app roach was applied to estimat e adjuste d vaccine effectiveness accounting for pot enti al confounders . Prespecified covaria tes in logistic reg ression mo dels included calend ar tim e in biweekly intervals, US Departmen t of Heal th and Human Se rvices region, age , sex, and self-repo rte d rac e and Hispanic ethnicity . We r epea ted the r egression by adding health s tatus indica tors an d SARS -CoV-2 exposure . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint variables pot enti ally associat ed with th e likelihood of vaccination and risk of Covi d-19 hospitaliza tion (detailed in Suppl No variable ge ner ated an absolu te chang e in the odds r atio of vaccination of more th an 5% in eithe r dir ection, which was a presp ecified cutoff, so no addition al variables were added to th e base model . Potential effect modification of prio r SA RS-CoV-2 infection (at least 14 days prior to th e curren t illness) was assessed using a likelihood ra tio t est (with a P- value <0.15 suggestive of effect modification).[21] Separa te ass pe rformed the test-n trol syndrome-negative con trol p to asse ss comparability of estima tes. Effectiven ess estimat es were very similar using the tes t-negative a nd syndrome-negative con trol gro ups. Ther e fore, cont rol groups were combined t o improve pr ecision. Vaccine effectiveness estima tes wer e str atified by age group (18-49, o years), SARS- CoV-2 vac cine product (Pfizer-BioNTech or Mode rna), SARS-CoV-2 variant, and u nderlying medical conditions with a pr evalence 20% in the mellitus, ch disease , chronic cardiovascular dis ease, and obesi t y (definitions provided in Supplemen tary App endix B). S ensitivit in Supplem enta ry Appendix B . Sta ta Version 16 (College Statio n, TX) and SAS 9.4 (Cary, NC) were used for statistical an alysis. RESULTS Participants We included 1210 pa tien ts (590 cases, 334 test-nega tive and 286 syndr ome-negative con trols) (Figure S1) enrolled from 18 clinical sites (Figure 1) over the course of 51 days (Figure S2). Overall , median age was 58 years, 276 (22.8%) w ere non-Hispa nic Black, 167 (13.8%) wer e Hispanic, and 248 (20.6%) had an immunocompromising co ndition (Table 1). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint After e xcluding pati ents with a vaccine dose 0-13 days before th e refe rence d ate, full SARS- CoV-2 vac cination had rec cases, 115 (36.7%) test-negative controls (Figure 2); 454 (83.5%) cases were unvaccinated. Among fully vaccinated pa tien ts, median t ime be twe en the las t vaccine dose and ons et of Covid-like symptoms was 44 days (interquar tile rang e [IQR] 25 to 5 4 days) for 45 cases and 42 days (IQR 27 to 60 days) for 115 test-nega 251 (96.5%) had source verification of vaccine doses. SARS-CoV-2 whole genome sequ e ncing was completed for 231 cases, with variant of concern B.1.1.7 the most commonly iden tified Vaccine effectiveness resul ts for full vaccination wer e very similar using the t est-n egative S4). Afte r combining contr ol groups, SARS-CoV-2 vaccine effectiveness for full vaccination to t Covid-19 hospitaliza tions was 86.9% (95% CI: 80.4-91.2%) (Figure 3). V was similar for Pfizer-BioNTech years (97.3%, 95% adul ts aged 65 yea rs, vaccine effectiveness was similar in th ose 65-74 years (87.9%, (9 5% significantly o mising 95% t o immunocompromi sed patie nts with an active solid organ or h emat ologic malignancy or solid organ tr fectiveness was 51.2% . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: (95% CI: -30.7-81.8%). Vaccine were lowe r for pati ents cardiovascular 76.0% (95% CI: 63.7-84.1%). Evidence of effect modification by prior lab ora tory-confirmed SARS-CoV-2 infection was not obs erved (likelihood r a tio tes t p-value = 0.55). Se nsitivity analys es produced r esults similar to th e primary analysis (Table S2). Breakthrough vac cine Covid -19 hospitali zations Forty-five Covid-19 case patients met ou r definition of being fully vaccinated befo re symptom onset . Among these , median age was 68 years (IQR 62-77 years), median time be tween the final vaccine dose and symptom onset was 44 days (IQR: 25 to 54 days), and 20 (44.4%) had an immunocompromising condition, including ac tive solid organ o r hematol ogic malignancy (n=9), and prior solid organ tr ansplan t (n=7). These break through cases includ e d 28 patients vaccina ted with t he Pfizer- BioNTech pro duct and 17 patien ts vaccinated with the Mod ern a product . In geograph ically dispersed sites in the US duri ng the e arly phase of th e SAR S-CoV-2 vaccination program, the two m RNA vaccines authori zed for use in the US wer e appr ox imately 87% effective for prevent ing Covid-19 hospitaliza tions, with similar effectiveness obse rved for t he Pfizer BioNTech an d Mode rna pro ducts. This analysis adds to early real-world evaluati ons tha t demons tra ted high vaccine effectiveness agains t Covid-19 in groups prioriti zed for e arly vaccination, such as healthca re worke rs.[22, 23] These resul t s also add to a limit ed . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint body of evidence tha t the S ARS-CoV-2 m RNA vaccines ar e highly effective for pre venting Covid-19 hospitaliz ations . These resul ts exp efficacy for SARS-CoV-2 mRNA vaccin es repor ted from phase 3 clinical trials .[3, 4] The trial s included patie nt popul ations h ealt hier at baselin e tha n those commonly hospitalized with Covid-19 an d were not pow ered to evalua te t he pro t ective ben efits of vaccination for preven ting sever e outco mes, such as hospitaliza tion . The design of this surveillance analysis with concurren t inclusion of pati ents hospit alized wit h Covid-19 and two separa te con trol groups enable d a robus t evalua tion of vaccine effectiveness for th e preven tion of severe Covid-19, including among patien ts with multiple a nd serious medical comorbi dities . Vaccination cover age in the two control gro ups was very similar to o ne anoth er and to vaccine upt ake in the US during the surveillance pe riod for this an alysis,[1] adding confidence to ou r vaccine effective ness results . The findings of high vac cine effectiveness in t he US adult p opulati on and acr oss subgroups defined by age, demographics, and como rbiditi es suggest tha t the mR NA vaccines ar e broadly eff ective for the preventi on of severe Covid-19, including in populatio ns at high risk of severe illn e ss. The prot ective ben efits of any vaccinatio n to cine. A histo ry of solid organ transpl ant an d oth er immunocompromising conditions have b een a ssociated with reduced cell-medi at ed and humor al immune respons es to SA RS-CoV-2 vaccines.[2 4, 25] Our results suggested substan tial nefit fro m vaccination in immunosuppressed p eo ple, with a vaccine effectiveness of about 60% for th e preve ntion of Covid-19 hospitalizati ons in this populati on. Howeve r, vaccine effectiveness was significantly lower in patien ts with immunocompromisi ng conditions compared t o hout immunocom promising conditions. Among pati ents wi th vaccine breakth rough Covid-19 hospitaliza tions i n this analysis, almost on e-half had an immunocompromising condition, mos t commonly a history of solid organ tr ansplan tati on or an ac tively trea ted maligna ncy. Immunosuppressive condi tions affect mil lions of adults in the Uni ted S ta tes.[26] Future work is ne eded . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint to unde rstand vaccine effective ness amo ng people with specific immunocompro mising conditions and the dur ability of prot ection in this popula tion to inform the ne ed for boos ter vacci nes and/or non-vaccine prevent ative int erven tions, such as mask use and social distancing. During implementa tion of the n ation al S ARS-CoV-2 vaccination program in Isra el betwee n December 2020 and Feb ruary 2021, th e Pfizer BioNTech vaccine produc t demons tra ted 87% vaccine effectiveness for the p reven tion of Covid-19 hospitalizati ons with a mean follow- up of 15 days.[27] Results of our US an alysis in a populatio n with a higher burde n of comorbiditi es demonstra ted simila r vaccine effectiveness for both the Pfizer BioNTech and M oder na mRNA vaccines with longer follow-up time (median 43 days and maximum 113 days). Evaluating the dura tion of pro tect ion from SARS-CoV-2 vaccines will require addi tional evaluati o n with longer follow-up time. This analysis had certain limit ations . Whi le we included cont rol groups th at wer e l ikely to reduce bias from differen tial h ealthc are seeking behavior, the re was pot ential for residual confounding. People who chose to b e vaccinated may have been mor e likely to engage in o the r behaviors to r educe their risk for Covid-19, such as mask use and avoiding large crowds. Adjus ting for self-report ed variabl es tes . Race Hispanic ethn icity differed be tween case and contr ol groups; this likely repr e sented und erlying differences in the incid ence of SARS-CoV-2 infection by race and et hnicity in the US and models were adjusted for rac e and e thnicity.[28] Alth o ugh vaccine effectiveness was lower in adults with immunocompromising conditions, these conditions ar e likely associat ed with varying severity of immunosuppression and this analysis was not powere d to look a t vaccine effectiveness among subgroups with individual immunocompr omising conditions. In an effort to cap tu re all COVID-19 cases admitt ed to pa rticipa ting hospit als durin g a period of high community transmissi on, enrollm ent of cases and controls was no t matched o n a day-t o-day basis; however, all cases an d contr ols were enr olled within a 51-day period and vaccine effect iveness models were adjust ed for calend ar time . For cer tain . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint exposur es or be haviors as mask use, ther e was a pote ntial for r ecall bias or s ocial desirabili ty bias. However, inclusion of th ese variabl es in adjusted models did no t substa ntively change vaccine effectiveness estima tes and they were n ot included in t he final models. Lastly, m ost sequenc ed viruses in this analysis were B.1 .1.7 varia nts, whi ch repres ent ed the majori ty of circulatin g viruses in the US during this time p eriod ;[1] vaccine effectiveness against ot her em erging variants will require add ition al study. In conclusion, th e SARS-CoV-2 mRNA vaccines were highly effective for preven tin g Covid-19 hospitaliz ations among ad ults in March t hrough May 2021. Widesp read vaccina ti on can be exp ect ed to have a major beneficial impact o n Covid-19 hospitaliza tions and associ ated outco mes, post-Covid complications.[29, 30] While SARS-CoV-2 mRNA vaccines appear t o substanti al benefit t o immunocompromised p eople , effectiveness is lower in this popul atio n t han in the immunocompeten t popul ation . It will be crucial to unde rstan d the b enefit of addi tional pr eventive measures, such as vaccine boos ters an d continued masking, in pa tien ts at highes t risk for vaccine breakth rough. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint Funding: Primary funding for this study was provided by the US Cent ers for Dise ase Control an d Prevention (75D30121F00002). The RED Cap data to ol was support ed by a Clinical and Translatio nal Science Award (UL1 TR002243) from the Natio nal Cent er for Advancing Transla tio nal Sciences. Potential Conflicts of Interest: Vaccine manufacture rs had no rol e in the cond uct, analysis, or dissemination of this work . The primary funder for this work was the US Cen ters f or Disease Contr ol and Prevention (CDC); C DC scientists part icipated in t his work and are includ ed as aut hors. The following poten tial conflicts of inte rest h ave been repor ted by th e auth ors. Dr. B rown repo rts grants fr om CD C duri ng the co ndu ct o f the s tu dy; perso nal fees from Hami lto n, ot her from Faron, ot her from Seda na, grants fro m Jans sen, grant s fro m NI H, grants from DoD, o ther from O x ford Un ivers i ty, other fro m Brig ham You ng Un ivers ity, o ut side t he s ubm itted work. Dr. Casey reports grant s from Nati o nal In st itute of Healt h, out side t he s ubm itted work. Dr. C hang w as a speaker for La Jolla Pharmace uti cals i n 2018, and co ns u lted for PureTech Healt h i n 2020. Dr. Chappe l l reports grants from CD C, grant s from NC ATS/N IH d uri ng the con du ct o f the st udy. Dr. Ex li ne reports o t her from Ab bott Lab s, out si de the s ubm it ted work. Dr. Files reports perso nal fees as c ons u ltant from Cyto vale, DSM B member from Med pace, out side t he s ubm itted work. Dr. Gaglani reports grants from CD C-Vanderb i lt, dur ing t he co nd uct of t he s tudy; grant s from CD C, grants fro m CD C, grants from CD C-Ab t, g rants from CDC-We stat, ou ts ide the sub m itted work. Dr. Gersheng orn report s perso nal fee s from Gilead S cie nces, I nc, o ut side t he s ubm itte d work. Dr. Ginde reports grants from C DC, d uri ng the c on d uct o f the stu dy; grants from Ab bV ie, grants from Faron Pharmaceuti cals, out si de the s ubm itted w ork. Dr. Gong reports grants from CD C, d urin g the c on duc t o f the st udy; grant s from NIH, gran ts fr om A HRQ, other fr om Regenero n, perso nal fees from Ph il ip s Healt hcare, out side t he s ubm itted work. Dr. Grijalva reports o ther from P fizer, ot h er from Merck, ot her from San o fi-Paste ur, grants fr om Camp be ll A ll iance /Sy neo s Healt h, grant s from Ce nters f or Disease Co ntrol a nd Prevent io n, grants from Nat i onal I nst it utes of Healt h, grants from Foo d and Drug Admi ni stratio n, grant s from A genc y for H ealth Care Research and Q ual ity, grant s fr om San of i, o uts ide the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint subm itte d work. Dr. Hager reports ot her f rom CDC via s ubc ontract w ith Vanderb ilt duri ng the co ndu ct o f the st udy; ot her from I ncy te Corp oratio n, other fro m Marcus Fo un dati on, o ther fro m EMPACT Precis io n Medic ine v VUM C, ou ts ide the s ub mitte d work. Dr. Halasa reports grant s from CD C duri ng t he co nd uct of t he st udy; grant s and n on- fi nanc ial s up port from Sano f i, grants from Qu ide l ou ts ide the s ub mitte d work. Dr. Khan reports grants from Un ite d Therapeut ics, grant s fro m Jo hn so n & Jo hn so n, grants from 4D Medica l, grants from Lu ng LLC, grant s fro m Reata Pharmaceutical s, out si de the s ub mitted work. Dr. Kwon reports grants from C DC, d uri ng the c on d uct o f the stu dy. Dr. Lauring report s perso nal fee s from Sano fi, persona l fees from Ro che, o uts ide t he su bmitte d work. Dr. Lind sel l reports gran ts f rom CDC, d uri ng t he con du ct o f the st udy; gran ts fr om NI H, grants fro m DoD, grant s from Marc us Fo un datio n, ot her from bioMer ieu x, ot her from End po in t LLC, ot h er from Entegri on I nc, o ut side t he s ubm it ted work; in ad dit io n, Dr. Lindse ll has a patent f or risk strati ficat i on i n sep si s and se pti c s hoc k i ss ued. Dr. Martin reports gran ts from Va nderbi lt Un ivers ity / Centers for D isease C on trol an d Prevent io n, dur ing t he cond uc t of t he st udy; persona l fees from Pf izer, grants from Me rck, out si de the s ubm itted w ork. Dr Monto repor ts consulting fees from Sanofi-Pasteur and S eqirus ou t side the submit ted work . Dr. Peltan reports grants from Ce nters for Di sease Co ntro l and Preve nti on, d uri n g the co nd uct of t he st udy; grant s from N ationa l In sti tute s o f Healt h, grants from Jan sse n Pharmaceut ic als, ot her from Asa hi Kasei P harma, other from Regenero n, out side t he s ubm itted work. Dr. Rice rep o rts grants fr om Ce nters f or Disease Co ntr ol, d urin g the c on du ct of t he st udy; pers onal fees from C umberl and Pharmaceut ical s, In c, perso nal fees fr om Av isa Pharma, LLC, persona l fees from Sa no fi, out si de the s u bmitte d work. Dr. Self report ed res earch funding from CD C for the curr ent p roject and consul ting fees o utside th e submitt ed work from Aep rio Pharmaceu ticals and Merck. The oth er au thors r epo rted n o p inte rest . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint REFERENCES 1. Centers for Disease Con trol and Pr eventi on. COVID : May 2021. 2. U.S. Foo d & Drug Administratio n. El Sahly HM, Essink B, et al . Efficacy and Safety of the mRNA-1273 SARS -CoV-2 Vaccine. N Engl J SJ, Kitchin N, et . Saf ety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020 ; 383(27): 2603-15. 5. Garg S, Kim L, Whitake r M, e t al. Hospi tal ization Ra tes an d Charact nts ed with COVID-NET, 14 States 1-30, 2020. MMWR M orb al Vaccine Effectiven ess for Prevention of Severe Influ enza-Associa ted Illness amon g Adults in the Uni ted S tat es, 2019-2020: A test-negative study. effectiveness agains t hospitaliz ation in the Uni ted S tat es, 2019-2020. J Infect Dis 2020 . 8. Ferdinands JM, Gaglani M, M artin ET, al. Preventi on of Influenza Hosp italiz atio n Among Adults in th e Unit ed Sta tes, 2015-2016: R esults From th e US Hospit alized Adult I nfluenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis 2019 ; 220(8): 1265-75. test-nega tive design for stu dies of the effectiveness of influenza vaccine. Vaccin e 2013 ; 31(30): 3104-9. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint 10. Lewnard JA, NP, et al . Theore tical framework for r et rospective s tudies of the effectiveness of SARS-CoV-2 vaccines. Epidemiology (Cambridge, Mass) 2021 . 11. World He , Olson SM, S elf WH, e t al. Effectiveness of Pfizer-BioNTech and Mo derna Vaccines Against COVID-19 Among Hospitaliz ed A dults Aged 65 Yea rs - United S tat es, Ja n uary-March 2021. MMWR Mo rb Mor tal Wkly Rep 70(18): 674-9. 13. Lauer SA, Gran tz Incu Peri od of Coronavirus Disease 201 9 (COVID-19 ) From Publicly Reporte d Confirmed Cases: Estimation an d Applica tion. A nn Int ern Med 2020 . 14. Feldstein LR, F erdin ands JM, S elf WH, e t al. Mode ling the impac ts of clinical influenza tes ting on influenza vaccine effectiveness es timat es . J Infect Dis 2021 . 15. Feldstein LR, S elf WH, Fer dinands J M, e t al. Incorp ora ting Real-t ime Influenz a Det ection In to th e Test-negative Design for Estimati ng Influenza Vaccine Effectiveness: The e Test-negative Design (rtTND). Clin Infect Dis 2021 ; 72 (9 ): 1669-75. 16. U.S. Foo d & Drug Administratio n. CDC 20 19-Novel Coronavirus (2019-nCoV) Real- Time htt ps://www.fda.gov/media/134922/download . , Holmes EC, O'Tool e \u00c1, e t al. A dynamic nomenclatur e prop osal for SA RS-CoV-2 lineages to assis CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint 19. Centers for Disease Con and Pr eventi on. In terim clinical conside rati ons for use of COVID-19 vaccines currently au thoriz ed in th e Unit ed Sta tes. Avail at: ht 1 Jun e 2021. 20. Jackson ML, Chung JR, Jackson LA, e t al. I nfluenza Vaccine Effectiveness in the U ni ted St ates during the 2015-2016 Season . N Engl 2017 ; 534-43. 21. Durand CP. Does raising type 1 erro r rat e improve power to d etec t int eracti ons in linear regression mod els? A simulati on study. P LoS One 2013 ; 8(8): e71079. 22. Thompson MG, Bu rgess JL, Nal eway AL, et al. Int erim Estimat es of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infectio n Among Health Car e Personn el, First R espond ers, and Oth er Essenti al and Fron tline Worke rs - Eight U.S. Locations, Decembe r 2021. MMWR Mo rb et al. erim Estimat es of Vaccine Effectiveness of Pfizer- BioNTech and M oder na COVID-19 Vaccin es Among Healt h Care Personn el - 33 U.S. Sites, Janua ry-March 2021. MMW Boyarsky BJ, We Avery Antibody Resp onse t o 2-Dose SARS-CoV-2 mRNA Vaccine Series ts. J AMA 2021 . 25. Ruddy JA, Connolly CM, Boyarsky BJ, e t a l. High antibody resp onse t o two-dose SA RS-CoV-2 messenger RN A vaccination in pa tien ts with rheuma tic musculoskele tal dise ases. Ann Dis 2021 . 26. Patel M, Chen J , Kim S, et al. A nalysis of Market Scan Data for Immunosup pressiv e Conditions and Hospitali zatio ns for Acute R espira tor y Illness, Unite d Sta tes. Eme rg Infect Dis 2020 ; 26(8): 1720-30. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint 27. Dagan N, Barda ten E, e t al. B NT162b2 mRNA Covid-19 Vaccine in a Nation wide Mass Vaccination Se tting. N Engl J Med 2021 ; 384(15): 1412-23. 28. Hollis ND, Li W, Van Dyke ME, et al. Racia l and Ethnic Disparities in I ncidence of SA RS-CoV-2 Infection, 22 US S tat es and DC, Janua ry 1-October 1 , 2020. Emerg Infect Dis 2021 ; 27(5): 1477- 81. 29. Zhou F, Yu T, Du R, et al. Clinical course a nd risk factors for mortali ty of adult inpa tients with COVID-19 in Wuhan, China: a re trospec ti ve cohort study. Lanc et 2020 ; 395(10229): 1054-62. 30. Roth GA, Emmons-Bell S, Alge r HM, e t al. Trends in Patient Cha racte ristics and CO VID-19 In- Hospital Mo rtali ty in the Uni ted S tat es During the COVID-19 Pandemic. JAM A Ne t w Open 2021 ; 4(5): e218828. 31. HealthDa ta.gov. COVID-19 repo rt ed pati ent impact an d hospital ca pacity by stat 20 21. 32. United S tat es Census Bure au. An nual esti mates of 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint TABLES AND FIGURES Table 1. Characteris tics of hospitaliz ed Covid-19 case and control pa tien ts \u2014 IVY Netwo rk, Unit ed Sta tes, March- M ay 2021. Characteristic Covid-19 Cases (N = 590) Combined Test- negative and Syndrom e-negative Controls (N = 620) Test-negative Controls (N = 334) Syndrom e-negative Controls (N = 286) Median age (IQR *) - years 56 (44 - 65) 61 (47 - 70) 62 (48 - 71) 59 (47 - 70) Age catego ry - no./to tal no 112/286 (39.2) Female (9.4) 37/334 (11.1) 21/286 (7.3) Non-Hispanic, all r races 48/590 (8.1) 19/620 (3.1) 12/334 (3.6) Unknown 10/590 2/620 (0.3) 1/334 1/286 (0.4) U.S. Census regio n - no./t otal n o. (%) East 103/590 (19.2) 32/286 (11.2) Residence in long-t erm car e facility - no. /total no. (%) 12/584 (2.1) 42/614 (6.8) 22/330 (6.7) 20/284 Health (31.3) 89/258 (34.5) work - no ./tot al no. (%) 33/477 (6.9) 33/569 (5.8) 15/311 (4.8) 18/258 (7.0) Education level : at tend ed some college o r more - no./to tal no ted always wearing mask when aro und others in public - no./to tal is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint Repor ted a tt ending 1 gath ering with m ore than 10 peopl e in past 2 weeks - no ./to t al no. (%) 167/443 (37.7) 145/552 (26.3) 62/303 (20.5) 83/249 (33.3) Number of medica tions - media n (IQR) 6 (2 - 11) 9 (4 - 14) 10 (5 - 14) 8 (3 - 13) Repor ted 1 h ospital admission in p ast year - no./to tal no. (%) 154/538 (28.6) 322/589 (54.7) 193/324 (48.7) Underlying medical tions - no ./tot a l no. (%) (2.4) 58/619 (9.4) (9.5) SARS-CoV-2 vaccination status - ./to l 454/590 (77.0) 274/620 days 46/590 (7.8) 28/620 (4.5) 21/334 (6.3) 7/286 vaccinated r eceived - no ./to tal no. (%) Moderna days be tween second vaccine dose and symptom onse t (or hospital admission for syndrom e-negativ e control group) - medi an (IQR) 44 (25 - 54) 43 (26 - 65) 42 (27 - 60) 47 (24 - 66.5) * IQR den otes in ter quar tile r ange Race and e thnic groups wer e rep ort ed by the pati ent o r proxy Long-term care facility include d repo rti ng living in a nursing home, assisted living home, or reh ab hospit al / other sub-ac ut e or chr onic facility before th e hospit al admission \u00a7 Chronic medical conditio n catego ries were ob tain ed thr ough perso nnel . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint \u00b6 Vaccination status was classified base d on the numbe r of mRNA vaccine doses r eceived befor e a refe rence d ate , which was the d at e of symptom onset for cases and test-n egati ve controls and da te of hospi tal admissio n for syndrome-negative con trols. U nvaccinated pa tien ts received no dos es of vaccine before th e r eference d at e, par tially vaccinated p ati e nts received on e of two doses of mRNA v accine 14 days before th e refe rence d at e or bot h doses with the second d ose rec eived <14 days before th e refe rence d at e, and fully vaccinated p atie nts received bo th doses of vaccine 14 days before th e refe rence d at e. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint Table 2. SARS-CoV-2 lineages identified y whole genome sequencing of upper res pirato ry specimens collected from Covid-19 cases \u2014 IVY Net work, United S tat es, Ma rch-May 2021. * SARS CoV-2 lineage Patients hospitalized with Covid-19 and SARS CoV-2 sequenci ng co mpleted Fully vaccinated cases (n =19) Partially vaccinated cases (n=17) First vaccine dose 0-13 days before symptom onset (n=15) Unvaccinated cases (n=180) All cases with sequencing complete d (n=231) Variants of concern B.1.1.7 7 11 11 109 138 P.1 2 2 0 9 13 B.1.429 0 0 0 9 9 B.1.351 1 0 1 2 4 Variants of inte res t B.1.525 0 0 0 2 2 B.1.526.1 1 1 0 4 6 B.1.526 0 0 0 3 3 Othe r varian ts B.1.1.519 0 0 1 6 7 B.1.2 2 0 0 2 4 B.1 1 0 1 1 3 B.1.621 0 0 0 3 3 B.1.526.2 1 0 0 1 2 B.1.623 0 0 0 2 2 R.1 0 0 0 1 1 B.1.612 0 0 0 1 1 B.1.526.3 0 0 0 1 1 B.1.361 0 0 0 1 1 B.1.517 0 0 0 1 1 Sequencing completed bu t lineage could no t be assigned 4 3 1 22 30 *Specimens with SA RS-CoV-2 detection by RT-P CR with cycle threshold <32 for at least one of two nucleocapsid gene targe ts tes ted und er went whole genome s equencing. S ARS-CoV-2 lineages were assigned using Pangolin genomes; 231/590 (39.2%) Co vid-19 cases had samples with complete se quencing. Of th ese 231 samples with complete se quencing, 201 (87.4%) had a lineage assigned. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint Figure 1. Map of continental Uni ted S ta t es with incidence of Covid-19 hospitaliza tions by stat e in April 2021 indicat ed by color (red). Participating sit es are sh own on the map with circles; the siz e of each circle re pre sents th e number of Covid-19 cases included from each site in this analysis -- IVY Network, Unit ed Sta te s, March-M ay 2021.* Figure 1 footnote: * Sources of id-19 hospitaliza tion da ta and popul atio n census data wer e Heal thData .gov and U nited St at es Census Bureau . [31, 32] . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint Figure 2. Vaccination status of pat ie nts (N=544), test-n egative (N=279) \u2014 IVY Netwo r k, es, March -May 2021. * . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint Figure 2 footnote: * Vaccination st atus was classified based on the numbe r of mRNA vaccine doses r eceived befor e a refere nce dat e, which was the da te of symptom onset (for cases and test-neg ativ e controls) or da te of hospital admission (for syndrome-nega ti ve controls). Unvaccinat ed pa tients recei ved no doses of mRNA vaccine before th e refe rence d ate , par tia lly vaccinated patie nts rec eived one of t wo doses of mRNA vaccine 14 days before th e refe rence da te or bo th doses with the second d ose re ceived <14 days before th e refe rence d at e, and fully vaccinated p atie nts rec eived both d oses of vaccine 14 days before the ref erenc e dat e. Pati ents who rec eive d the first dose of a SARS-CoV-2 vaccine 0-13 days before the refere nce dat e (46 cases; 21 test-n egativ e controls ; 7 syndrome-negative con ) were excluded from this analysis. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint Figure 3. Vaccine oV-2 mRNA vaccines for the preven tion of Covid-19 hospitalizations over all and b y subgroups \u2014 I VY Netwo rk, Unit ed Sta . * . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2021. ; https://doi.org/10.1101/2021.07.08.21259776doi: medRxiv preprint Figure 3 footnote: * The analysis included case pa tien ts wit h Covid-19-like illness who tested positiv e for SARS-CoV-2 infection and con trol pa tien ts combined from two groups, including a (1) test-negative contr ol group with Covid-19-like illness and negative SARS-CoV-2 testing and (2) a syndrome-negative cont rol group without Covid-19-like illness and negativ e for SARS-CoV-2. Vaccine effectiveness models were adjust ed for calendar time in biweekly inte rvals, U S Departmen t of Heal th and Human Se rvices region, age in years, sex , race an d ethnici ty. Vaccinatio n status was classified based on the number of m RNA vaccine doses received b efore a r efer ence da te, which was defined as the dat e of symptom onset for cases and test-nega tive cont rols and da te of hospit t rols. Unvaccinat ts rece d vaccinat ed pati ents r eceived one of two doses of vaccine 14 days before th e refe rence d ate o r both d oses wit h the second dos e received <14 days befor e th e refe rence d ate, a nd fully vaccinated pati ents r eceive d both doses of vaccine 14 days before th e refe rence da te. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted "}